Loading clinical trials...
Loading clinical trials...
The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
NCT03633708 · Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT04922892 · Secondary Hyperparathyroidism;Parathyroidectomy
NCT06434961 · Secondary Hyperparathyroidism
NCT04064827 · Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
NCT02859896 · Secondary Hyperparathyroidism-Chronic Kidney Disease
Guangdong Provincial People's Hospital
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions